Equities
  • Price (EUR)3.26
  • Today's Change-0.01 / -0.31%
  • Shares traded0.00
  • 1 Year change-16.46%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

bioXXmed AG, formerly CytoTools AG, is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.

  • Revenue in EUR (TTM)44.48k
  • Net income in EUR-3.94m
  • Incorporated2006
  • Employees0.00
  • Location
    bioXXmed AGRiedstrasse 2DARMSTADT 64295GermanyDEU
  • Phone+49 61 519515812
  • Fax+49 61 519515813
  • Websitehttps://cytotools.de
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.